Jinyu Bio-Technology Co Capital Expenditures
The Capital Expenditures (CapEx) of Jinyu Bio-Technology Co (600201.SS) as of Oct 12, 2026 is -121.43 M CNY. In the previous year, Capital Expenditures (CapEx) was -89.67 M CNY — a change of 35.42% (lower).
Get this data via API
Financial Data API
Capital Expenditures
-121.43 MCNY
YoY
35.42%
Last updated:
The Jinyu Bio-Technology Co Capital Expenditures history
3 Years
10 Years
25 Years
Max
| YEAR | Capital Expenditures | YoY |
|---|---|---|
| -121.43 MCNY | +35.42% | |
| -89.67 MCNY | -67.18% | |
| -273.17 MCNY | +43.69% | |
| -190.11 MCNY | -48.99% | |
| -372.68 MCNY | +63.23% | |
| -228.32 MCNY | -25.72% | |
| -307.36 MCNY | -43.65% | |
| -545.47 MCNY | +35.70% | |
| -401.95 MCNY | +199.41% | |
| -134.25 MCNY | -48.82% | |
| -262.29 MCNY | +26.94% | |
| -206.63 MCNY | — |
Jinyu Bio-Technology Co Stock analysis
Frequently Asked Questions about Jinyu Bio-Technology Co stock
Capital Expenditures (CapEx) of Jinyu Bio-Technology Co is -121.43 M CNY in 2025.
Capital Expenditures (CapEx) of Jinyu Bio-Technology Co changed from -89.67 M CNY to -121.43 M CNY, representing a 35.42% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Jinyu Bio-Technology Co since 2006 – with annual values, charts, and detailed analysis.
Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.
Capital Expenditures (CapEx)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Jinyu Bio-Technology Co historically and in real time.
Cash Flow — Jinyu Bio-Technology Co
All Key Metrics — Jinyu Bio-Technology Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth